High Capacity & Robustness for mAb Purification
TOYOPEARL AF-rProtein A-650F affinity resin is well-suited for capturing of antibodies out of high titre feedstocks. It combines a high binding capacity at short residence time and fast mass transfer kinetics with alkaline stability.
TOYOPEARL AF-rProtein A-650F affinity resin is well-suited for capturing of antibodies out of high titre feedstocks. It combines a high binding capacity at short residence time and fast mass transfer kinetics with alkaline stability. The typical dynamic binding capacity for IgG is higher than 30 mg/mL resin at two minutes residence time. Thus, Toyopearl AF-rProtein A-650F offers the opportunity to improve process economics by increasing both, throughput and robustness. The high binding capacity helps to minimize the resin and buffer volumes needed for a given target load. Applying higher flow rates reduces loading and cycle times in lab scale and process scale purifications.
A newly developed recombinant ligand (non-animal-derived) has been engineered to maintain capacity even after repeated exposure to alkaline solution. Its multipoint attachment to the TOYOPEARL polymeric matrix further enhances chemical and thermal stability. In practice this pays off for a low level of protein A leaching and also for a high resistance to alkaline solutions employed in cleaning-in-place (CIP) procedures. As a consequence the number of cycles can be increased when compared to Protein A resins with lower caustic stability.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Fast and Efficient Sialic Acid Clone Selection Using Lectin-Based High-Throughput Screening
June 2nd 2025Glycosylation is a common and critical post-translational modification that affects protein function and therapeutic efficacy, making its monitoring and accurate quantification essential for drug development.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
